Integrated Publication Strategy for Novel Immunotherapy
How we developed a comprehensive publication plan resulting in 12 peer-reviewed publications over 18 months, effectively communicating the scientific story of a breakthrough immunotherapy.
Client
Emerging Biotech Company
Therapeutic Area
Immunology / Autoimmune Disease
Project Duration
18 Months
Deliverables
12 peer-reviewed publications, 8 congress presentations
The Challenge
Our client, an emerging biotech company, had developed a first-in-class immunotherapy treatment for a severe autoimmune condition. After completing their Phase 2 trials with promising results, they were preparing for Phase 3 while also engaging with potential commercial partners. They faced several critical challenges:
- Their novel mechanism of action was complex and not well understood by the medical community
- Multiple aspects of their clinical data needed to be communicated (efficacy, safety, quality of life, biomarkers)
- Limited internal resources to manage an extensive publication program
- Needed to establish scientific credibility to attract commercial partners and investment
- Tight timelines to communicate results ahead of competitive products in development
The company needed a strategic publication plan that would effectively communicate their scientific story to multiple audiences, including clinicians, researchers, potential partners, and investors.
Key Publication Challenges
Complex Scientific Story
Novel mechanism with multi-faceted clinical implications
Diverse Author Networks
Coordinating multiple global KOLs across various publications
Strategic Journal Selection
Identifying optimal journals for maximum scientific impact
Data Fragmentation
Multiple datasets needing coherent narrative integration
Our Approach
EloquiMed worked closely with the client's medical affairs and clinical teams to develop a comprehensive, strategic publication plan:
1. Strategic Publication Planning
We conducted a thorough data assessment and developed a strategic publication plan that mapped all available and upcoming data against key scientific messages. This included a gap analysis to identify where additional analyses might be needed to support the scientific narrative.
2. Author and Journal Strategy
We helped identify and engage key opinion leaders with relevant expertise for each publication. Our journal selection strategy balanced impact factor considerations with audience reach and publication timelines, targeting both specialty and high-impact general medical journals.
3. Coordinated Content Development
Our medical writers with immunology expertise developed manuscript drafts that maintained consistency across the publication plan while highlighting unique aspects of each paper. We implemented a robust author engagement process that facilitated meaningful contributions while maintaining timelines.
4. Congress Strategy Integration
We aligned the publication plan with key congress opportunities, developing abstracts, posters, and oral presentations that complemented the peer-reviewed publications and amplified key messages through multiple channels.
12
Peer-Reviewed Publications
8
Congress Presentations
Results & Impact
Scientific Recognition
Successfully published 12 papers, including two in top-tier journals with impact factors >20. Three publications were selected as "Editor's Choice" with accompanying editorials.
KOL Engagement
Built relationships with 15+ global opinion leaders who became ongoing advocates for the therapy. Enhanced the company's scientific reputation within the immunology community.
Business Impact
The publication strategy directly supported a successful partnership deal valued at $120 million upfront with $1.8 billion in potential milestones. Enhanced investor confidence leading to a successful funding round.
"EloquiMed's strategic approach to our publication planning transformed how we communicated our science. Their deep therapeutic expertise and publication knowledge helped us deliver a cohesive scientific story that resonated with researchers, clinicians, and partners. The impact on our business has been tremendous."
Publication Timeline
Mechanism of Action & Preclinical Data
Month 1-4
- Primary MOA paper in top immunology journal
- Two supporting preclinical papers in specialty journals
- Oral presentation at major immunology congress
Phase 1 Safety & Pharmacokinetics
Month 3-7
- Phase 1 clinical results in specialty clinical journal
- Pharmacokinetic/pharmacodynamic analysis in clinical pharmacology journal
- Two poster presentations at clinical specialty meeting
Phase 2 Primary Results
Month 8-12
- Primary Phase 2 results in high-impact general medical journal
- Complementary late-breaking abstract at major clinical congress
- Post-hoc analysis of rapid responders in specialty journal
Phase 2 Secondary Endpoints & Biomarkers
Month 12-18
- Quality of life outcomes publication in patient-focused journal
- Biomarker analysis paper in translational medicine journal
- Long-term safety follow-up data at clinical congress
- Review article synthesizing the entire data package in leading opinion journal
Related Case Studies
Comprehensive IB Development for Immunology Trials
Development of a comprehensive Investigator Brochure for a first-in-class immunotherapy entering Phase II trials.
Global PBRER Strategy for Oncology Product
Development of a comprehensive PBRER for a novel oncology therapy addressing emerging safety signals while maintaining a positive benefit-risk profile.
Successful FDA BLA Submission in Oncology
How we helped a mid-size biotech company achieve first-cycle approval for their novel cancer therapy.
Ready to develop your publication strategy?
Partner with EloquiMed to craft a strategic publication plan that effectively communicates your scientific story to the right audiences at the right time.